More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market
Biogen, PatientsLikeMe use Fitbit to better understand MS
The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.
Five things for pharma marketers to know: Monday, April 13
Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan’s name and Sanofi enters an auto-immune disease collaboration.
Biogen adds football, basketball talent for MS campaign
MS drugmaker Biogen Idec drafted Tyler Campbell, son of NFL Hall of Fame running back Earl Campbell, and former Dallas Mavericks point guard Chris Wright to help inspire sufferers of multiple sclerosis.
Supreme Court says Teva MS patent stands (for now)
January 20, 2015
7:00 pm
The ruling stalls generics until at least September.
Patients to influence voice of Lemtrada consumer campaign
Patient advocates lobbied the FDA to approve the MS drug and Sanofi subsidiary Genzyme says their voice will be part of the consumer outreach when DTC rolls out next year.
Gilenya fails to help primary progressive MS patients
Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Avonex (interferon beta-1a) on some measures among relapse-remitting MS patients.
Sanofi wants greater MS role
September 11, 2014
5:36 pm
The plan is to bring in-house products to the market as well as through acquisitions.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix